Dark

HALO
Halozyme Therapeutics, Inc.
stock NASDAQ

At Close

Aug 14, 2026 3:59:58 PM EDT

98.64USD-2.016%(-2.03)1,658,682

94.84Bid 104.07Ask 9.23Spread

Pre-market

Aug 14, 2026 9:00:30 AM EDT

100.63USD-0.040%(-0.04)200

After-hours

Aug 14, 2026 4:55:30 PM EDT

98.00USD-0.649%(-0.64)1,239

OverviewOptionsHistoricalExchangesShortsNews

Jan 12, 2022

03:04AM EST Halo Collective Expands Into Functional Beverages, Agrees To Acquire H2C Beverages RTTNews

Jan 10, 2022

08:52AM EST Halozyme Sees FY22 Revenue $530M-$560M Vs $442.23M Est; Sees Adj. EPS $2.05-$2.20 Vs $1.85 Est Benzinga

08:49AM EST Halozyme Therapeutics, Inc. (HALO) said it expects fiscal 2022 non-GAAP earnings per share to be $2.05 to $2.20. For 2022, the company expects GAAP earnings per share of $1.90 to $2.05. For 2022, Halozyme expects GAAP net income of $270 million to $295 million and non-GAAP net income of $290 million to $315 million. RTTNews

08:31AM EST Halozyme Therapeutics Expects 2022 EPS Of $1.90 To $2.05 And 2022 Non-GAAP EPS Of $2.05 To $2.20 RTTNews

08:01AM EST HALOZYME PROVIDES 2022 FINANCIAL GUIDANCE AND OUTLOOK PR Newswire

Jan 6, 2022

03:18PM EST IIROC Trade Resumption - HALO PR Newswire

02:48PM EST IIROC Trading Halt - HALO PR Newswire

Jan 4, 2022

08:36AM EST Halo Collective Apoints Sky Pinnick As Chief Marketing Officer RTTNews

08:03AM EST Halozyme to Present Virtually at the 40th Annual J.P. Morgan Health Care PR Newswire

Dec 13, 2021

04:05PM EST HALOZYME APPOINTS NEW GENERAL COUNSEL PR Newswire

Dec 10, 2021

07:50AM EST The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares Benzinga

Dec 9, 2021

09:57PM EST Halozyme Announces $750M Buyback Over The Next Three Years Benzinga

04:01PM EST HALOZYME ANNOUNCES $750 MILLION THREE-YEAR SHARE REPURCHASE PROGRAM PR Newswire

Dec 2, 2021

06:52AM EST Janssen's Subcutaneous Darzalex Combo Wins FDA Approval For Pretreated Multiple Myeloma Benzinga

Dec 1, 2021

02:22PM EST (daratumumab and hyaluronidase-fihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse PR Newswire

Nov 30, 2021

05:11PM EST Halo Collective Confirms Stock Symbol Reverts Back to HCANF PR Newswire

Nov 24, 2021

07:33AM EST Wells Fargo Maintains Overweight on Halozyme Therapeutics, Lowers Price Target to $58 Benzinga

Nov 22, 2021

08:39AM EST Halo Collective Confirms Akanda Submission Of Draft Registration Statement For Proposed IPO RTTNews

Nov 18, 2021

09:03AM EST Halozyme to Present at Upcoming Investor Conferences PR Newswire

Nov 4, 2021

09:12AM EDT Halo Collective To Acquire Simply Sweet Gummy RTTNews

Nov 3, 2021

11:42AM EDT Halozyme's Q3 Sales Boosted By Darzalex; Lifts FY21 Earnings Outlook Benzinga

09:16AM EDT JMP Securities Maintains Market Outperform on Halozyme Therapeutics, Raises Price Target to $55 Benzinga

09:16AM EDT SVB Leerink Maintains Outperform on Halozyme Therapeutics, Lowers Price Target to $48 Benzinga

Nov 2, 2021

06:30PM EDT UPDATE: Halozyme Therapeutics Q3 Adj. EPS $0.55 Beats $0.42 Estimate, Sales $115.83M Beat $101.94M Estimate Benzinga

04:57PM EDT Halozyme Therapeutics Raises EPS Guidance From $1.85-$2.00 To $1.90-$2.00, Raises Sales Guidance From $425M-$445M To $430M-$445M Benzinga

04:56PM EDT Halozyme Therapeutics Q3 EPS $1.48 Up From $0.25 YoY, Sales $115.83M Beat $101.94M Estimate Benzinga

04:02PM EDT Halozyme Reports Third Quarter 2021 Results PR Newswire

10:54AM EDT The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US Benzinga

10:41AM EDT Earnings Scheduled For November 2, 2021 Benzinga

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 19, 2021

04:06PM EDT Halozyme To Host Third Quarter 2021 Financial Results Webcast and Conference PR Newswire

Sep 15, 2021

04:05PM EDT Halozyme to Participate in the 2021 Cantor Virtual Global Healthcare Conference PR Newswire

Aug 26, 2021

09:02AM EDT Halozyme to Present at Wells Fargo 2021 Virtual Healthcare Conference PR Newswire

Aug 10, 2021

07:55AM EDT The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts Benzinga

Aug 9, 2021

05:30PM EDT Halozyme Therapeutics: Q2 Earnings Insights Benzinga

04:42PM EDT Halozyme Therapeutics, Inc. (HALO) released a profit for its second quarter that advanced from last year. RTTNews

04:05PM EDT UPDATE: Halozyme Raises FY21 Guidance: Sales From $375M-$395M To $425M-$445M vs $404.6M Estimate, Adj. EPS From $1.55-$1.70 To $1.85-$2 vs $1.41 Est. Benzinga

04:04PM EDT Halozyme Therapeutics Q2 Adj. EPS $0.66 Beats $0.40 Estimate, Sales $136.50M Beat $103.16M Estimate; Raises Guidance Benzinga

04:02PM EDT Halozyme Q2 EPS $0.62 Vs. $0.19 Year Ago RTTNews

04:01PM EDT Halozyme Reports Second Quarter 2021 Results PR Newswire

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

04:11AM EDT Earnings Scheduled For August 9, 2021 Benzinga

Aug 8, 2021

10:11AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Jul 30, 2021

08:01AM EDT Halozyme to Participate in Canaccord Genuity 41st Annual Growth Conference PR Newswire

Jul 27, 2021

04:06PM EDT Halozyme To Host Second Quarter 2021 Financial Results Webcast and Conference PR Newswire

Jul 15, 2021

07:44AM EDT High Tide And Halo Closes Sale Of KushBar Assets To Halo RTTNews

07:42AM EDT High Tide and Halo Announce Closing of Sale of KushBar Assets to Halo PR Newswire

Jul 12, 2021

09:09AM EDT Janssen's Darzalex Faspro Wins FDA Approval In Combination With Pomalidomide, Dexamethasone For Multiple Myeloma Benzinga

08:20AM EDT Halozyme Announces Janssen Gets FDA Approval Of DARZALEX FASPRO In Combination With Pomalidomide And Dexamethasone RTTNews

08:15AM EDT Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO In Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse Benzinga

08:13AM EDT (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse PR Newswire

Jun 22, 2021

01:49PM EDT Halozyme Announces Janssen Receives European Marketing Authorizations For DARZALEX (daratumumab) Subcutaneous Formulation For Newly Diagnosed Systemic Light-Chain Amyloidosis And Pre-Treated Multiple Myeloma Benzinga

01:49PM EDT DARZALEX(r) (daratumumab) Subcutaneous Formulation for Newly Diagnosed Systemic Light-chain Amyloidosis and Pre-Treated Multiple Myeloma PR Newswire

08:12AM EDT The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal Benzinga

06:29AM EDT GSK- Pfizer's ViiV To Develop 'Ultra-Long-Acting' HIV Drugs With $215M Halozyme Deal Benzinga

05:12AM EDT ViiV Healthcare, Halozyme Enter Global Collaboration and License Agreement for ENHANZE Drug Delivery Technology to Enable Development of Ultra-long-acting Medicines for HIV Benzinga

02:22AM EDT ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE(r) drug delivery technology to enable development of "ultra long-acting" medicines for HIV Business Wire

02:21AM EDT ViiV Healthcare, Halozyme Sign Global Collaboration And License Deal For ENHANZE Drug Delivery Technology RTTNews

02:19AM EDT for ENHANZE(r) drug delivery technology to enable development of "ultra-long-acting" medicines for HIV PR Newswire

Jun 14, 2021

10:47AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2021 Benzinga

08:50AM EDT Evercore ISI Group Initiates Coverage On Halozyme Therapeutics with Outperform Rating Benzinga

Jun 1, 2021

04:18PM EDT Halozyme Highlights Data Presentations By Collaborators For Therapies Utilizing ENHANZE At 2021 American Society Of Clinical Oncology Annual Meeting Benzinga

04:01PM EDT Halozyme Highlights Data Presentations by Collaborators for Therapies Utilizing PR Newswire

May 28, 2021

04:41PM EDT Halozyme to Present at Upcoming Investor Conferences PR Newswire

May 21, 2021

10:29AM EDT Janssen Gets Two Positive CHMP Opinions For Darzalex RTTNews

10:16AM EDT Halozyme : Janssen Gets Two Positive CHMP Opinions For DARZALEX Subcutaneous Formulation Utilizing ENHANZE RTTNews

10:03AM EDT Halozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX Subcutaneous Formulation Utilizing ENHANZE Benzinga

10:03AM EDT Halozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX(r) PR Newswire

May 17, 2021

10:10AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 17, 2021 Benzinga

08:59AM EDT Halo Collective Q1 Loss/Shr $0.01 Vs Loss/Shr $0.03 Prior Year RTTNews

08:05AM EDT SVB Leerink Initiates Coverage On Halozyme Therapeutics with Outperform Rating, Announces Price Target of $56 Benzinga

May 11, 2021

10:07AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2021 Benzinga

07:30AM EDT Piper Sandler Downgrades Halozyme Therapeutics to Neutral, Lowers Price Target to $48 Benzinga

May 10, 2021

05:07PM EDT Halozyme Announces Co. Plans To Buyback Up To $49M In Common Stock This Year Benzinga

04:27PM EDT Halozyme Therapeutics Sees FY21 EPS $1.55-$1.70 Vs. $1.55 Est., Sales $375M-$395M Vs. $389.96M Est. Benzinga

04:27PM EDT Halozyme Therapeutics Q1 EPS $0.19 Misses $0.32 Estimate, Sales $89.02M Beat $84.88M Estimate Benzinga

04:02PM EDT Halozyme Reports First Quarter 2021 Results PR Newswire

04:09AM EDT Earnings Scheduled For May 10, 2021 Benzinga

May 7, 2021

10:07AM EDT Earnings Outlook for Halozyme Therapeutics Benzinga

Apr 29, 2021

04:06PM EDT Halozyme to Present at BofA Securities 2021 Virtual Health Care Conference PR Newswire

Apr 20, 2021

04:06PM EDT Halozyme To Host First Quarter 2021 Financial Results Webcast And Conference PR Newswire

Feb 25, 2021

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

Feb 24, 2021

10:49PM EST Halozyme Therapeutics Announces Pricing Of Private Offering Of $700 Mln Of Convertible Senior Notes Due 2027 RTTNews

10:42PM EST Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 PR Newswire

09:59AM EST Halozyme Therapeutics shares were trading lower after the company reported worse-than-expected Q4 EPS results and issued FY21 EPS and sales guidance below estimates. Benzinga

07:30AM EST The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO Benzinga

Feb 23, 2021

04:31PM EST Recap: Halozyme Therapeutics Q4 Earnings Benzinga

04:10PM EST Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of PR Newswire

04:03PM EST Halozyme Sees FY21 Sales $375M-$395M Vs 400M Estimates, EPS $1.40-$1.55 Vs $1.7 Estimates Benzinga

04:02PM EST Halozyme Therapeutics Q4 EPS $0.50 Misses $0.53 Estimate, Sales $121.70M Beat $120.16M Estimate Benzinga

04:01PM EST Halozyme Reports Fourth Quarter 2020 Results And Full Year 2020 Results PR Newswire

07:25AM EST The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts Benzinga

04:09AM EST Earnings Scheduled For February 23, 2021 Benzinga

Feb 22, 2021

10:07AM EST Halozyme Therapeutics's Earnings: A Preview Benzinga

Feb 10, 2021

04:06PM EST Halozyme To Host Fourth Quarter And Full Year 2020 Financial Results Webcast PR Newswire

07:34AM EST The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga

Feb 9, 2021

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Feb 6, 2021

05:19AM EST Halo Agrees To Acquire Two Additional Los Angeles Dispensary License Applicants RTTNews

Feb 5, 2021

07:44AM EST The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street Benzinga

Feb 4, 2021

07:22AM EST The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs Benzinga

Feb 2, 2021

09:04AM EST Halo Announces OTCQX Ticker Symbol Change to HCANF PR Newswire

Jan 26, 2021

11:13AM EST IIROC Trade Resumption - HALO PR Newswire

08:07AM EST The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market Benzinga

Jan 25, 2021

03:56PM EST IIROC Trading Halt - HALO PR Newswire

Jan 21, 2021

08:05AM EST The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping Benzinga

Jan 20, 2021

07:32AM EST The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study Benzinga

Jan 15, 2021

05:31PM EST (Daratumumab And Hyaluronidase-fihj) As Treatment For Newly Diagnosed Patients With Light Chain (AL) Amyloidosis PR Newswire

07:57AM EST The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges Benzinga

Jan 14, 2021

07:57AM EST The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates Benzinga

Jan 11, 2021

08:20AM EST Halozyme Expects 2021 EPS Of $1.40 To $1.55, Represents 55%-70% Growth Over Expected 2020 EPS RTTNews

08:17AM EST Halozyme Sees FY 2021 Revs $375M-$395M Vs $622.3M-$653.63M Est Benzinga

08:01AM EST Halozyme Provides 2021 Financial Guidance Highlighted By Strong Revenue And EPS PR Newswire

Jan 8, 2021

07:25AM EST The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs Benzinga

Jan 4, 2021

08:02AM EST Halozyme To Present Virtually At The 39th Annual J.P. Morgan Healthcare PR Newswire

Dec 23, 2020

08:31AM EST The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut Benzinga

01:32AM EST Halozyme Announces Roche Gets EU Approval For Phesgo Utilizing Halozyme's ENHANZE Technology RTTNews

01:26AM EST (Fixed-Dose Combination Of Perjeta(r) And Herceptin(r) For Subcutaneous Injection) Utilizing Halozyme's ENHANZE(r) Technology For The Treatment Of Patients With HER2-Positive Breast Cancer PR Newswire

Dec 18, 2020

04:48PM EST Halo Closes Acquisition Of Winberry Farms RTTNews

Dec 17, 2020

10:17AM EST Benzinga's Top Upgrades, Downgrades For December 17, 2020 Benzinga

09:55AM EST Berenberg Initiates Coverage On Halozyme Therapeutics with Buy Rating, Announces Price Target of $50 Benzinga

Dec 10, 2020

07:42AM EST The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations Benzinga

Dec 8, 2020

08:04AM EST The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings Benzinga

Dec 6, 2020

08:41AM EST Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace Benzinga

Nov 23, 2020

09:12AM EST A Look Into Halozyme Therapeutics's Debt Benzinga

09:07AM EST Halozyme Therapeutics Raises FY2020 Sales Guidance from $250M-$260M to $265M-$275M Benzinga

08:11AM EST Horizon Therapeutics Plc And Halozyme Enter Global Collaboration And License Deal For ENHANZE Technology RTTNews

08:10AM EST Halozyme Raises FY20 GAAP EPS Guidance From $0.80-$0.85 To $0.90-$0.95 vs $0.86 Est., Raises Sales Guidance From $250M-$260M To $265M-$275M vs $255.12M Benzinga

08:08AM EST Halozyme Therapeutics Raises FY2020 Sales Guidance from $250.00M-260.00M to $265.00M-275.00M Benzinga

08:07AM EST Halozyme Licenses' its Drug Delivery Technology to Horizon Theerapeutics, Halozyme Receive $30M Upfront Payment Benzinga

08:07AM EST Halozyme Lifts 2020 Outlook RTTNews

08:05AM EST Halozyme Raises Full Year 2020 Guidance PR Newswire

08:01AM EST Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global PR Newswire

Nov 20, 2020

09:49AM EST Halozyme Therapeutics Option Alert: Dec 18 $44 Calls at the Ask: 800 @ $0.75 vs 100 OI; Ref=$38.38 Benzinga

Nov 19, 2020

08:17AM EST The Daily Biotech Pulse: Aquestive's Positive FDA Meeting, Prevail Awarded Patent, Neuro-Oncology Conference Gets Underway Benzinga

Nov 18, 2020

04:01PM EST Halozyme To Participate In Fireside Chat For The Piper Sandler 32nd Annual PR Newswire

07:30AM EST The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted Benzinga

Nov 16, 2020

11:54AM EST Wells Fargo Maintains Overweight on Halozyme Therapeutics, Raises Price Target to $60 Benzinga

Nov 13, 2020

10:01AM EST Halozyme Reports Positive CHMP Opinion For Roche's Phesgo, Herceptin Utilizing Co.'s ENHANZE Technology For HER2-Positive Breast Cancer Benzinga

10:00AM EST Combination Of Perjeta(r) And Herceptin(r) For Subcutaneous Injection) Utilizing Halozyme's ENHANZE(r) Technology For HER2-Positive Breast Cancer PR Newswire

07:40AM EST The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations Benzinga

Nov 12, 2020

08:30AM EST Halozyme: FDA And EMA Seeking Approval Of Daratumumab SC Formulation, Known As DARZALEX FASPRO In The U.S. RTTNews

08:18AM EST Halozyme Therapeutics Announces Janssen Has Submitted US And EU Applications Seeking Approval Of DARZALEX FASPRO Benzinga

08:15AM EST Approval Of DARZALEX FASPRO(tm)/ DARZALEX(r) Subcutaneous (SC) Formulation Utilizing ENHANZE(r) Technology, Combination With Pomalidomide And Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma PR Newswire

07:44AM EST The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal Benzinga

Nov 10, 2020

08:40AM EST The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies Benzinga

Nov 6, 2020

09:50AM EST Halozyme Therapeutics, Inc. (HALO) shares are rising on Friday morning, as the company is set to replace Mednax Inc. in the S&P MidCap 400. RTTNews

07:47AM EST The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold Benzinga

Nov 5, 2020

07:42PM EST MGIC Investment & Halozyme Therapeutics Set To Join S&P MidCap 400 RTTNews

06:41PM EST MGIC Investment & Halozyme Therapeutics Set to Join S&P MidCap 400; First PR Newswire

05:23PM EST S&P Dow Jones Indices Reports 'MGIC Investment & Halozyme Therapeutics Set to Join S&P MidCap 400; First Bancorp, The Geo Group & Mednax to Join S&P SmallCap 600' Benzinga

08:26AM EST Halozyme Announces Upcoming Data Presentations At American Society Of Hematology Annual Meeting For APOLLO And ANDROMEDA Phase 3 Studies By Janssen Evaluating Subcutaneous Daratumumab Utilizing ENHANZE Benzinga

08:15AM EST Hematology Annual Meeting For APOLLO and ANDROMEDA Phase 3 Studies By Janssen Evaluating Subcutaneous Daratumumab Utilizing ENHANZE(r) PR Newswire

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

Nov 4, 2020

08:21AM EST The Daily Biotech Pulse: Alzheimer's Conference Underway, Biogen's Aducanumab Briefing Doc, Supernus Earnings Benzinga

Nov 3, 2020

07:38AM EST The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure Benzinga

Nov 2, 2020

04:06PM EST Halozyme Raises FY20 EPS Guidance From $0.60-$0.75 To $0.80-$0.85 vs $0.69 Est., Raises Sales Guidance From $230M-$245M To $250M-$260M vs $235.94M Est. Benzinga

04:04PM EST Halozyme Therapeutics Q3 EPS $0.25 Beats $0.20 Estimate, Sales $65.30M Beat $60.91M Estimate Benzinga

04:02PM EST Halozyme Reports Third Quarter 2020 Results And Raises Full Year 2020 Guidance PR Newswire

07:55AM EST Earnings Scheduled For November 2, 2020 Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 22, 2020

08:02AM EDT Halozyme To Host THIRD Quarter 2020 Financial Results webcast and Conference PR Newswire

Oct 21, 2020

08:04AM EDT The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings Benzinga

Oct 6, 2020

10:35AM EDT Halozyme Therapeutics shares are trading higher after the company announced the expansion of its collaboration and licensing agreement with Argenx for its ENHANZE Technology. Benzinga

05:22AM EDT Halozyme Announces Expansion of Collaboration and License Agreement With argenx for ENHANZE Technology Benzinga

02:17AM EDT Halozyme Announces Expansion Of Collaboration And License Deal With Argenx For ENHANZE Technology RTTNews

02:15AM EDT Halozyme Announces Expansion Of Collaboration And License Agreement With argenx PR Newswire

Sep 23, 2020

09:21AM EDT IIROC Trade Resumption - HALO PR Newswire

09:12AM EDT IIROC Trading Halt - HALO PR Newswire

Sep 17, 2020

09:56AM EDT Halo Announces At-The-Market Equity Financing Program Business Wire

08:30AM EDT Halozyme Announces Poster Presentation Of Data From Roche's Phase 1b Study Evaluating Atezolizumab For Subcutaneous Administration Utilizing Enhanze In Non-Small Cell Lung Cancer Benzinga

08:12AM EDT Halozyme Announces Poster Presentation Of Data From Roche's Phase 1b Study Evaluating Atezolizumab RTTNews

08:01AM EDT Evaluating Atezolizumab For Subcutaneous Administration Utilizing Enhanze(r) In Non-Small Cell Lung Cancer PR Newswire

Sep 10, 2020

09:37AM EDT Halozyme Unveils Janssen Submission For FDA Approval Of DARZALEX FASPRO For Light Chain Amyloidosis RTTNews

08:14AM EDT Halozyme Announces Janssen Submission For FDA Approval Of DARZALEX FASPRO For The Treatment Of Patients With Light Chain Amyloidosis Benzinga

Sep 9, 2020

08:02AM EDT Halozyme To Present At Upcoming Virtual Investor Conferences PR Newswire

Sep 2, 2020

04:02PM EDT Halozyme To Participate In 2020 Wells Fargo Virtual Healthcare Conference PR Newswire

Aug 14, 2020

08:26AM EDT The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal Benzinga

Aug 10, 2020

04:03PM EDT Halozyme Sees FY20 GAAP EPS $0.60-$0.75, Sales $230M-$245M vs $234.8M Estimate Benzinga

04:03PM EDT Halozyme Therapeutics Q2 EPS $0.19 Misses $0.25 Estimate, Sales $55.20M Miss $66.68M Estimate Benzinga

04:01PM EDT Halozyme Reports Significant Recent Achievements And Second Quarter 2020 Results PR Newswire

04:10AM EDT Earnings Scheduled For August 10, 2020 Benzinga

Aug 4, 2020

04:06PM EDT Halozyme To Present At Canaccord Genuity 40th Annual Growth Conference PR Newswire

Jul 29, 2020

04:06PM EDT Halozyme To Host Second Quarter 2020 Financial Results Webcast And Conference PR Newswire